RxDoctor Payments Data

Uday Kanakadandi, MD

Interventional Cardiology · Urbana, ILNPI 1003086182

Payments from drug & device makers

$12,521in general payments, 2019–2025

Across 79 payments — averaging $158.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Philips North America LLC$3K
  • Abiomed$425
  • Boston Scientific$291
  • Medtronic$200
  • Shockwave Medical, Inc$156
  • plus $293 from 7 others

What the payments were for

  • Consulting fees$1,00011%
  • Speaking & faculty fees$1,50016%
  • Travel & lodging$3,02633%
  • Food & beverage$3,69540%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,521 in reported general payments places this provider in the 55th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$111,015
Medicare patients
1,023
Services billed
1,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban151$182,362
EntrestoSacubitril/Valsartan103$117,033
JardianceEmpagliflozin41$48,759
Repatha SureclickEvolocumab56$44,120
XareltoRivaroxaban43$36,470
BrilintaTicagrelor35$26,314
Icosapent Ethyl21$7,522
VascepaIcosapent Ethyl13$4,356
Atorvastatin Calcium217$3,113
Metoprolol Succinate228$3,112
Carvedilol191$3,053
ClopidogrelClopidogrel Bisulfate183$3,002
Ezetimibe92$2,680
Rosuvastatin Calcium136$2,216
Losartan Potassium113$1,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$33$117,033103 claims
Boehringer IngelheimJardiance$14$48,75941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Urbana

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →